Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vertex | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 122.80B | -230x | 2.02 | USD 479.79 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.1% Upside | Upgrade to Pro+ | |
Regeneron Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 74.54B | 17x | 1.65 | USD 698.74 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 35.2% Upside | Upgrade to Pro+ | |
Lonza Group AG | OTC Markets | Healthcare | Biotechnology & Medical Research | USD 45.64B | 67.1x | USD 63.15 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.9% Upside | Upgrade to Pro+ | ||
argenx ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 37.48B | -916x | -11.66 | USD 624.67 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.1% Upside | Upgrade to Pro+ | |
IQVIA Holdings | NYSE | Healthcare | Biotechnology & Medical Research | USD 32.84B | 24.8x | 8.93 | USD 188.80 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.5% Upside | Upgrade to Pro+ | |
BeiGene ADS | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 29.71B | -2.01 | USD 271.80 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 3.5% Upside | Upgrade to Pro+ | ||
BioNTech | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 26.98B | -56x | 0.5 | USD 112.92 | 3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.5% Upside | Upgrade to Pro+ | |
ICON PLC | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 15.27B | 19.8x | 0.71 | USD 190.02 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.9% Upside | Upgrade to Pro+ | |
Insmed | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 14.70B | -14.6x | 3.69 | USD 81.55 | 3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.4% Upside | Upgrade to Pro+ | |
United Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 14.36B | 13x | 0.58 | USD 320.05 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.4% Upside | Upgrade to Pro+ | |
Genmab AS | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 14.26B | 13.2x | 0.15 | USD 22.68 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.4% Upside | Upgrade to Pro+ | |
Summit Therapeutics PLC | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 13.64B | -58.4x | -1.11 | USD 20.69 | 11.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 11.90B | -3.3x | -0.16 | USD 30.96 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 45.3% Upside | Upgrade to Pro+ | |
WuXi Biologics | OTC Markets | Healthcare | Biotechnology & Medical Research | USD 11.83B | 22.9x | -2.35 | USD 5.75 | -2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
WuXi Biologics | OTC Markets | Healthcare | Biotechnology & Medical Research | USD 11.83B | -2.35 | USD 2.80 | -3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Neurocrine | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 11.79B | 34.5x | 1.06 | USD 118.72 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39% Upside | Upgrade to Pro+ | |
Exelixis | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 10.80B | 21.4x | 0.12 | USD 38.69 | 2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0.9% Upside | Upgrade to Pro+ | |
Sarepta | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 10.28B | 43.2x | 0.72 | USD 106.75 | 3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Medpace Holdings | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 9.92B | 25x | 0.61 | USD 327.32 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.9% Upside | Upgrade to Pro+ | |
Bio-Techne | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 9.72B | 61.5x | -2.19 | USD 61.75 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40% Upside | Upgrade to Pro+ | |
Tempus AI | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 9.52B | -10x | 0.14 | USD 56.18 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.5% Upside | Upgrade to Pro+ | |
Vaxcyte | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 9.34B | -19x | 0.55 | USD 73.02 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ascendis Pharma AS | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 9.13B | -22.1x | -0.98 | USD 156.58 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.7% Upside | Upgrade to Pro+ | |
EXACT Sciences | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 8.78B | -40.1x | 0.02 | USD 47.41 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 46.8% Upside | Upgrade to Pro+ | |
Charles River Laboratories | NYSE | Healthcare | Biotechnology & Medical Research | USD 8.43B | 825.3x | -8.28 | USD 165.31 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.6% Upside | Upgrade to Pro+ | |
Qiagen | NYSE | Healthcare | Biotechnology & Medical Research | USD 8.28B | 102.8x | -1.35 | USD 38.40 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.3% Upside | Upgrade to Pro+ | |
Revolution Med | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 7.54B | -11.2x | 1.81 | USD 40.74 | 4.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Madrigal Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 7.52B | -15.4x | 0.47 | USD 341.27 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.4% Upside | Upgrade to Pro+ | |
Legend Bio | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 6.40B | -18.1x | -0.59 | USD 35.01 | -4.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Telix Pharmaceuticals ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 6.22B | 210.1x | 0.25 | USD 17.98 | -4.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.7% Upside | Upgrade to Pro+ | |
Blueprint Medicines Corp | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 6.16B | -89.2x | -1.01 | USD 96.57 | 6.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 43.8% Upside | Upgrade to Pro+ | |
Alkermes Plc | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 5.57B | 15.4x | 4.45 | USD 34.33 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.6% Upside | Upgrade to Pro+ | |
Verona Pharma ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 5.49B | -27.7x | 0.18 | USD 69.63 | 3.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.7% Upside | Upgrade to Pro+ | |
Cytokinetics Inc | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 5.40B | -8.4x | -3.95 | USD 46 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Nuvalent | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 5.31B | -18.8x | 0.35 | USD 74.98 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 49.3% Upside | Upgrade to Pro+ | |
Ionis Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 5.29B | -13.3x | 0.61 | USD 33.19 | 5.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Krystal Biotech | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 4.99B | 57x | 0.09 | USD 179.25 | 3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.9% Upside | Upgrade to Pro+ | |
TG | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 4.35B | -299.1x | -6.68 | USD 30.09 | 5.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
SpringWorks | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 4.34B | -16.5x | -0.52 | USD 57.76 | 8.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 34.8% Upside | Upgrade to Pro+ | |
PureTech Health | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 4.26B | -58.8x | 0.07 | USD 17.80 | -3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ultragenyx | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 3.96B | -6.7x | -0.29 | USD 42.92 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Crispr Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 3.76B | -10x | 0.09 | USD 43.92 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Akero Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 3.73B | -12.9x | 0.29 | USD 49.12 | 2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biohaven Pharma | NYSE | Healthcare | Biotechnology & Medical Research | USD 3.70B | -4.2x | 0.14 | USD 37.18 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Scholar Rock | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 3.66B | -15.4x | USD 38.82 | 7.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 33.2% Upside | Upgrade to Pro+ | ||
Immunovant | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 3.50B | -7.8x | 0.21 | USD 20.60 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Alvotech | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 3.46B | -7.2x | -0.24 | USD 11.36 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Rhythm Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 3.43B | -12.6x | 0.4 | USD 54.91 | 3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 38.4% Upside | Upgrade to Pro+ | |
Crinetics Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 3.32B | -9.6x | 6.01 | USD 35.78 | 7.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Arcellx | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 3.32B | -133.2x | -1.18 | USD 64.82 | 5.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |